glp-1 weight loss clinical trials GLP1 agonists: current and future landscape of for patients with metabolic dysfunction Study finds GLP-1 receptor agonists

Spending on glucagonlike peptide1 receptor agonists, or GLP1s, in the United States increased over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, according to the Journal of the American Heart Association, Although these medications were initially developed to treat Type 2 diabetes, newer indications now include weight management

Its biological functions are vast and critical: Primary Antioxidant: It is the most abundant intracellular antioxidant

2024 (expected)

Improved Mood and Cognitive Function Vitamin B12 supports brain health by assisting in the production of neurotransmitters like serotonin and dopamine, which regulate mood and emotional well-being

Circulation , 150 (2), 151161